Stock Ratings / Health Care / CTKB / dividends

PACB (44) NAUT (43) ALMR (55) LAB (27) ⌘ Pro Terminal →

Cytek Biosciences Inc. (CTKB) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.13 -2.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.09

Cytek Biosciences Inc. (CTKB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $796.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTKB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CTKB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.13 (-2.70% 1D, market cap $796.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTKB ranks #364 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CTKB compare to PACB and NAUT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $809.7M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTKB?

▼

Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.09 (-0.68%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTKB)Realized 20D OHLCV Swing Band: ±10.3%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY CTKB SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (±10.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (24% of score)

Altman Z-Score 4.76 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.35-0.2% Next Q

Q2 (-2Q)

Grade D$5.34+12% Next Q

Q3 (-1Q)

Grade D$5.98+2.5% Next Q

Current

Grade D$6.13-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTKB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTKB currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.34) and Max Pain ($6.44) forces dealer call-delta covering toward $6.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTKB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTKB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTKB)

✓Walkthrough of CTKB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTKB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.55%▲ ASCENDING CHANNEL

2026-11-03O $6.30H $6.30L $6.13C $6.13VOL 1.87M

RES: $6.63SUP: $4.85SMA50: $5.34SMA200: $4.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTKB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTKB Butterfly Map → + Track CTKB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTKB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTKB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTKB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTKB)

Health Care Rank #364 of 1016 ⚔️ PACB vs CTKB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTKB vs. PACB, NAUT, ALMR, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytek Biosciences Inc. (CTKB) ranks #364 by composite RQD confidence (45/100, grade D) and #383 by equity capitalization ($796.8M). Within this direct 5-issuer industry benchmark cohort, CTKB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with CTKB at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTKB ACTIVE Cytek Biosciences Inc.	D	45/100	—	51.8%	-12.7%	-2.70%	$796.8M	Benchmark Subject
PACB Pacific Biosciences of California Inc.	D	44/100	—	28.6%	-35.0%	-10.17%	$809.7M	/pacb-vs-ctkb →
NAUT Nautilus Biotechnology Inc.	D-	43/100	—	—	-35.0%	-13.06%	$347.7M	/naut-vs-ctkb →
ALMR Alamar Biosciences Inc.	D+	55/100	—	—	—	-10.11%	$2.12B	/almr-vs-ctkb →
LAB Standard BioTools Inc.	E	27/100	—	49.9%	-28.7%	-1.61%	$240.7M	/lab-vs-ctkb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001831915

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytek Biosciences Inc. (CTKB) reported GAAP revenue of $201.5M (+0.5% vs. FY2024 revenue of $200.5M , and +4.4% cumulative change since FY2023) , GAAP net income of -$66.5M, operating cash flow of -$4.7M, and free cash flow of -$8.8M (-140.1% YoY). On the balance sheet, CTKB closed FY2025 with $461.5M in total assets against $0 in total debt (Altman Z-Score: 4.76, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$201.5M	-$66.5M	-$4.7M	-$8.8M	$461.5M	—
FY2024 (FY)	2024-12-31	$200.5M	-$6.0M	$25.4M	$21.9M	$499.5M	—
FY2023 (FY)	2023-12-31	$193.0M	-$12.1M	$5.3M	$5.3M	—	—

3. CTKB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTKB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CTKB compare to PACB and NAUT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CTKB?

Where is CTKB trading relative to its 50-day, 200-day, and 52-week technical levels?

CTKB last traded at $6.13 (-2.70% on volume of 1,866,615 shares), positioning the stock +14.79% above its 50-day simple moving average ($5.34) and +31.55% above its 200-day simple moving average ($4.66). Across its 52-week range of $3.31 to $6.34, CTKB sits at the 93.1% percentile with a 14-day RSI of 62.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.3% ($5.50 to $6.76).

CTKB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CTKB pay a dividend and is it safe?

Cytek Biosciences Inc. (CTKB) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CTKB RQD Cockpit CTKB 12M Forecast CTKB Earnings & Move CTKB Dividends & DRIP CTKB Insiders & 13F CTKB Whale Options CTKB Profit Sankey CTKB News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CTKB — Cytek Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:32:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CTKB scores 45 out of 100 for a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 7 / 20. Per the RQD rating, this reflects ROIC of -12.7% and FCF yield of -1.07%. For a prospective investor, the company is not currently generating a return on invested capital or free cash flow to shareholders, so the valuation case must rest on future improvement rather than present cash generation.
Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and indicates some institutional interest, though the source data does not itemize the holders behind it.
Insider Conviction: 3 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-side conviction in the stock.
Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. The stock moves in line with the broader market, so it offers no defensive cushion and carries the same macro exposure as the index.
Forensic Balance Sheet: 11 / 20. Per the RQD rating, Altman Z is 4.76, Piotroski F is 3/9, and Debt/Equity is 0.5. The Z-score points away from distress, but the weak Piotroski reading and negative operating trend temper that comfort.

Taken together, the rating frames CTKB as a name where the present operating picture is weak, with the main support coming from institutional positioning rather than fundamentals or insider behavior. The price-to-value tradeoff is that a stock with negative ROIC and negative free cash flow yield depends on a turnaround in profitability that the source data does not yet show. Upside would need evidence of margin repair; without it, the rating points to continued distribution risk.

Business

Cytek Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Per the company profile, it has a market capitalization of $0.8B. The source data does not describe its specific products, customer base, or revenue model beyond the sector and industry classification. Per the financials, FY 2025 revenue was $201.5M.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$201.5M	$-40.4M	$-66.5M	N/A	$-8.8M	$90.9M	N/A
FY 2024	$200.5M	$-20.5M	$-6.0M	N/A	$21.9M	$98.7M	N/A
FY 2023	$193.0M	$-27.8M	$-12.1M	N/A	$5.3M	N/A	N/A

Per the market data, the company reports a gross margin of 51.8%, an operating margin of -20%, and a net margin of -33%. ROIC is -12.7%. Per the RQD rating, the Altman Z-Score is 4.76 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Revenue has been broadly flat across the three periods, while net income deteriorated sharply in FY 2025 to $-66.5M. Cash declined from $98.7M to $90.9M over the latest year.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the catalysts are largely routine: multiple market-wire items on CTKB estimates and market action, a stock-analysis item describing a "modest fair value lift" as analysts weigh profitability, and a Yahoo Finance item noting analysts estimate a decline in earnings. Also per the feed, the company will report Q3 2026 financial results on November 4, 2026, and a CEO and CFO will join a November 17 fireside chat with a live webcast. All news items carry a YELLOW light and MARKET WIRE impact label. The earnings-decline estimate is the most material risk item in the feed. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's primary products and customers, and how do they drive the FY 2025 revenue of $201.5M?
What caused the net loss to widen from $-6.0M in FY 2024 to $-66.5M in FY 2025, and is the operating loss expected to narrow?
What are the EPS and debt figures for the reported periods, given that the source lists them as N/A?
What is the consensus analyst rating and price target, given that analyst data is unavailable?
Who are the institutional holders behind the Whale 13F Flow pillar score, given that holder data is unavailable?

CTKB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cytek Biosciences Inc. (CTKB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CTKB Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability

Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 19h ago

Cytek Biosciences, Inc. Estimates – NASDAQ:CTKB

TradingView report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 22h ago

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for

Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A CEO and CFO will join a Nov. 17 fireside chat. Cytek will offer a live webcast.

Stock Titan report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

What Cytek Biosciences Buyers Were Betting On

Simply Wall St report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Yahoo Finance report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CTKB Q3'26 Earnings: revenue estimate is 53.05M USD

TradingView report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Morgan Stanley keeps USD 5.00 target for Cytek Biosciences stock

ad-hoc-news.de report covering Cytek Biosciences Inc. (CTKB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTKB Bull vs. Bear Conversation Board — What's Your Call at $6.13?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTKB 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.54 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CTKB (D • RQD 45/100) a Buy at $6.30?

Welcome to the CTKB (Cytek Biosciences Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.29 (-16.0%)

Spot @ $6.30

Pump the brakes on CTKB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CTKB, but look at what you are paying: current EV/EBITDA multiples with 51.8% gross margins. Unless Cytek Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.18 (+14.0%)

Spot @ $6.30

CTKB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CTKB, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $6.30 (52-wk range $3.31 - $6.34), any beat on forward guidance forces shorts and underweight funds to chase.